B+
Bull case
25%
Probability
Target price
$1.15
Analysis reference price unavailable
Analysis 2026-06-25 · RankAlpha Sentiment Codex
ZYBT
Zhengye BiotechnologyFNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
Primary-source earnings context supports a real veterinary-vaccine operating business with 2025 regulatory approvals, progress on overseas registrations, a stated R&D and product-portfolio agenda, and year-end cash of RMB50.3 million despite the downturn [#PR-EARNINGS-2026-04-29].
Posture
Defensive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta 0.0.
What can break
Commercial payoff from new approvals, export registrations, R&D spending, and companion-animal expansion plans remains unproven in reported results [#PR-EARNINGS-2026-04-29].
Momentum
79
Value
55
Sentiment
0
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $0.68 · Bull $1.15 · Bear $0.32Analysis 2026-06-25; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-11 • Model: HYBRID_IC_RP
AI Memo
As of 2026-06-25 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-11
Investment thesis
As of 2026-09-11
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-11. Definitions
Supporting evidence
What
Grade F · Defensive
Confidence Medium · Net Neutral
Why
Momentum79 · Δ7d -
Value55 · Δ7d 0.0
Sentiment0 · Δ7d -
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Confirming evidence
- • Value remains the lead driver in the composite, 7D delta 0.0.
Contradictions & invalidation
- • Commercial payoff from new approvals, export registrations, R&D spending, and companion-animal expansion plans remains unproven in reported results [#PR-EARNINGS-2026-04-29].
- • FY2025 revenue, gross profit, and earnings deteriorated materially, showing high sensitivity to China's swine cycle and vaccine pricing [#PR-EARNINGS-2026-04-29].
- • FY2025 was a sharp deterioration year: revenue fell to RMB116.4 million from RMB186.4 million, gross margin dropped to 20.5% from 49.0%, and net income swung to an RMB83.0 million loss, while the stock is now also under a Nasdaq bid-price deficiency notice [#PR-EARNINGS-2026-04-29][#PR-2026-06-04].
Catalyst clock
2026-09-30
Any H2 2026 swine-demand stabilization would matter disproportionately
Lead driver: Value · See fundamentals
Momentum
79
9% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
55
28% active weight
Current posture
7d trendFlat
Δ7d
0.0
Δ21d
-0.2
Sentiment
0
62% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade F. Momentum 78.8 / Value 55.1 / Sentiment 0.0
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-06-25. Scenario method
Most likely
B
Base case
45%
Probability
Target price
$0.68
Analysis reference price unavailable
Analysis 2026-06-25 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$0.32
Analysis reference price unavailable
Analysis 2026-06-25 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$45.18M
Beta
-
Shares Out
29.73M
P/E (TTM) · Derived
-7.4
P/S (TTM)
-
P/FCF (TTM) · Derived
41.76
Rev YoY
-
EPS YoY
-
Gross Margin
+20.4%
Op Margin
-60.7%
Net Debt
$3.32M
Current Ratio
1.14
As of 2026-09-11 • Updated nightlySource: Internal modelMethods & Data